Meropenem/Vaborbactam

美罗培南/韦博巴坦

Report date: 2024/12/31 14:01:33
QIDP

Base Information

Drug NameMeropenem/Vaborbactam
Drug Alias NameVaborbactam and Meropenem美罗培南+VABOMERE美罗培南和VABOMEREVaborbactam/Meropenem美洛培南+Vaborbactam +[16] 
ClassificationSmall molecules > Heterocyclic drugs > AntibioticsSmall molecules > Heterocyclic drugs > Antibiotics > β-lactam antibiotics > Carbapenems antibiotics
Mechanisms of ActionBacterial penicillin-binding protein inhibitorsBeta Lactamase inhibitors
TargetsBeta LactamaseBacterial penicillin-binding protein
Therapy Area/IndicationsHospital-acquired pneumoniaPyelonephritisUrinary Tract Infections +[10] 
Global Approved IndicationsUrinary Tract InfectionsPneumoniaRespiratory Tract Infections +[6] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2017/08/29
Country/TerritoryCzechiaBulgariaUnited States +[26] 
CombinationsYes MeropenemVaborbactam
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesMelinta Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesMelinta TherapeuticsXediton Pharmaceuticals IncMenarini Group +[8] 
Inactive CompaniesMenarini International Operations Luxembourg S A AMelinta Therapeutics Inc
Active IndicationsHospital-acquired pneumoniaPyelonephritisUrinary Tract Infections +[9] 
Inactive IndicationsPneumonia, Ventilator-Associated

Other Information

ATC CodeJ01DH
Related LinksWikipediaKEGG